SEARCH

SEARCH BY CITATION

References

  • Armstrong, R. A., A. B. Syed, and C. U. Smith. 2008. Density and cross-sectional areas of axons in the olfactory tract in control subjects and Alzheimer's disease: an image analysis study. Neurol. Sci. 29:2327.
  • Benson, S. C., H. A. Pershadsingh, C. I. Ho, A. Chittiboyina, P. Desai, M. Pravenec, N. Qi, J. Wang, M. A. Avery, and T. W. Kurtz. 2004. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43:9931002.
  • Braak, H., and E. Braak. 1991. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 82:239259.
  • Brunjes P. C., and M. C. Kenerson. 2010. The anterior olfactory nucleus: quantitative study of dendritic morphology. J. Comp. Neurol. 1:16031616.
  • Camacho I. E., L. Serneels, K. Spittaels, P. Merchiers, D. Dominguez, and B. De Strooper. 2004. Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J. Neurosci. 1:1090810917
  • Djordjevic, J., M. Jones-Gotman, K. De Sousa, and H. Chertkow. 2008. Olfaction in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging 29:693706.
  • Dubois, B., H. H. Feldman, C. Jacova, J. L. Cummings, S. T. Dekosky, P. Barberger-Gateau, A. Delacourte, G. Frisoni, N. C. Fox, D. Galasko, et al. 2010. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 9:11181127.
  • Friston, K. J., C. D. Frith, P. F. Liddle, and R. S. J. Frackowiak. 1991. Comparing functional (PET) images: the assessment of significant change. Cereb. Blood Flow Metab. 11:690699.
  • Friston, K. J., K. J. Worsley, R. S. J. Frackowiak, J. C. Mazziotta, and A. C. Evans. 1993. Assessing the significance of focal activations using their spatial extent. Hum. Brain Mapping 1:210220.
  • Gard, P. R. 2002. The role of angiotensin II in cognition and behaviour. Eur. J. Pharmacol. 1:114.
  • Gard, P. R. 2004. Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression. Expert Opin. Ther. Targets 8:714.
  • Heneka, M. T., M. Sastre, L. Dumitrescu-Ozimek, A. Hanke, I. Dewachter, C. Kuiperi, K. O'Banion, T. Klockgether, F. Van Leuven, and G. E. Landreth. 2005. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1–42 levels in APPV717I transgenic mice. Brain 128:144253.
  • Iadecola, C., and M. Nedergaard. 2007. Glial regulation of the cerebral microvasculature. Nat. Neurosci. 10:13691376.
  • Kehoe, P. G., and G. K. Wilcock. 2007. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol. 6:373378.
  • Klotz, L., M. Sastre, A. Kreutz, V. Gavrilyuk, T. Klockgether, D. L. Feinstein, M. T. Heneka. 2003. Noradrenaline induces expression of peroxisome proliferator activated receptor gamma (PPARgamma) in murine primary astrocytes and neurons. J. Neurochem. 86:907916.
  • Korczyn, A. D., and V. Vakhapova. 2007. The prevention of the dementia epidemic. J. Neurol. Sci. 15:24.
  • Kovacs, T., N. J. Cairns, and P. L. Lantos. 1999. b-Amyloid deposition and neurofibrillary tangle formation in the olfactory bulb in ageing and Alzheimer's disease. Neuropathol. Appl. Neurobiol. 25:481491.
  • Lacourcière, Y., J. M. Krzesinski, W. B. White, G. Davidai, H. Schumacher. 2004. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press. Monit. 9:203210.
  • Landreth, G. 2007. Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease. Curr. Alzheimer Res. 4:159164.
  • Lerner, A., and A. Bagic. 2008. Olfactory pathogenesis of idiopathic Parkinson disease revisited. Mov. Disord. 15:10761084.
  • Li, W., J. D. Howard, and J. A. Gottfried. 2010. Disruption of odour quality coding in piriform cortex mediates olfactory deficits in Alzheimer's disease. Brain 133:27142126.
  • Luna-Medina, R., M. Cortes-Canteli, M. Alonso, A. Santos, A. Martínez, and A. Perez-Castillo. 2005. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J. Biol. Chem. 3:2145321462.
  • Mogi, M., J. M. Li, K. Tsukuda, J. Iwanami, L. J. Min, A. Sakata, T. Fujita, M. Iwai, and M. Horiuchi. 2008. Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. Biochem. Biophys. Res. Commun. 24:446449.
  • Morales-Garcia, J. A., R. Luna-Medina, C. Alfaro-Cervello, M. Cortes-Canteli, A. Santos, J. M. Garcia-Verdugo, and A. Perez-Castillo. 2010. Peroxisome proliferator-activated receptor γ ligands regulate neural stem cell proliferation and differentiation in vitro and in vivo. Glia. 59:293307.
  • Papademetriou, V. 2005. Hypertension and cognitive function. Blood pressure regulation and cognitive function: a review of the literature. Geriatrics 60:2024.
  • Pearson, R. C., M. M. Esiri, R. W. Hiorns, G. K. Wilcock, and T. P. Powell. 1985. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer's disease. Proc. Natl. Acad. Sci. USA 82:45314534.
  • Price, J. L. 2004. Olfactory system. Pp. 11971211 in G. R. Paxinos, ed. The human nervous system 2nd. Academic Press, New York .
  • Price, J. L., P. B. Davis, J. C. Morris, and D. L. White. 1991. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol. 12:295312.
  • Saito, T., N. Iwata, S. Tsubuki, Y. Takaki, J. Takano, S. M. Huang, T. Suemoto, M. Higuchi, and T. C. Saido. 2005. Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat. Med. 11:434439.
  • Saiz-Sanchez, D., I. Ubeda-Bañon, C. de la Rosa-Prieto, L. Argandoña-Palacios, S. Garcia-Muñozguren, R. Insausti, and A. Martinez-Marcos. 2010. Somatostatin, tau, and beta-amyloid within the anterior olfactory nucleus in Alzheimer disease. Exp. Neurol. 223:347350.
  • Sakai, Y., H. Kumano, M. Nishikawa, Y. Sakano, H. Kaiya, E. Imabayashi, T. Ohnishi, H. Matsuda, A. Yasuda, and A. Sato. 2006. Changes in cerebral glucose utilization in patients with panic disorder treated with cognitive-behavioral therapy. Neuroimage 33:218226.
  • Sastre, M., I. Dewachter, S. Rossner, N. Bogdanovic, E. Rosen, P. Borghgraef, B. O. Evert, L. Dumitrescu-Ozimek, D. R. Thal, and G. Landreth. 2006. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc. Natl. Acad. Sci. USA 10:443448.
  • Talairach, J., and P. Tournoux. 1988. Co-planar stereotactic atlas of the human brain. 1st ed. Thieme, Stuttgart , Germany . pp. 37110.
  • Wada, K., A. Nakajima, K. Katayama, C. Kudo, A. Shibuya, N. Kubota, Y. Terauchi, M. Tachibana, H. Miyoshi, and Y. Kamisaki. 2006. Peroxisome proliferator-activated receptor gamma-mediated regulation of neural stem cell proliferation and differentiation. J. Biol. Chem. 5:1267312681.
  • Wang, N., L. Verna, N. G. Chen, H. Li, B. M. Forman, and M. B. Stemerman. 2002. Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J. Biol. Chem. 13:3417634181.
  • Watson, G. S., B. A. Cholerton, M. A. Reger, L. D. Baker, S. R. Plymate, S. Asthana, M. A. Fishel, J. J. Kulstad, P. S. Green, and D. G. Cook. 2005. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry 13:950958.